Atherosclerosis and apoproteins B and A-I
Related Experiment Videos
Insights
Measuring apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I) provides crucial insights into coronary artery disease (CAD) risk beyond standard cholesterol levels. These apoproteins help identify individuals at risk, even with normal cholesterol, highlighting metabolic links between lipoproteins.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Biochemistry
Background:
- The lipid hypothesis links coronary artery disease (CAD) risk to cholesterol levels, specifically high LDL cholesterol and low HDL cholesterol.
- Current risk assessment often relies on measuring cholesterol in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) fractions.
- However, standard lipid profiles may not fully capture an individual's CAD risk.
Purpose of the Study:
- To evaluate the added value of measuring apolipoprotein B (apoB) and apolipoprotein A-I (apoA-I) in assessing CAD risk.
- To explore the relationship between apoprotein levels and various dyslipoproteinemic syndromes associated with premature CAD.
- To determine if apoprotein measurements offer a more comprehensive understanding of the metabolic links between LDL and HDL.
Main Methods:
- Review of existing data on plasma levels of apoB and apoA-I in relation to CAD risk.
- Analysis of specific patient groups with conditions like HyperapoB, Familial Combined Hyperlipidemia (FCH), and Familial Hypercholesterolemia (FH).
- Comparison of risk assessment using standard lipid profiles versus those including apoprotein measurements.
Main Results:
- Measurement of apoB and apoA-I provides additional information for CAD risk assessment, detecting at-risk individuals even with normal cholesterol levels.
- Increased LDL particles, indicated by elevated apoB, are a common factor in syndromes associated with premature CAD.
- Low apoA-I levels may indicate decreased HDL2, a combination with elevated apoB that is particularly atherogenic.
Conclusions:
- Apoprotein measurements, specifically apoB and apoA-I, offer a more nuanced assessment of CAD risk than cholesterol levels alone.
- These apoproteins reveal metabolic links between LDL and HDL that might be obscured by standard lipid testing.
- Optimal assessment of dyslipoproteinemia in patients at risk for CAD should include apoB and apoA-I levels alongside cholesterol and HDL cholesterol measurements.
Abstract:
The lipid hypothesis stipulates that the risk of developing CAD is related to the cholesterol levels of various lipoprotein fractions, the risk increasing with either a higher LDL cholesterol level or a lower HDL cholesterol level. The data reviewed here indicate that the measurement of the plasma level of the major apoproteins of LDL and HDL, apoB and apoA-I, respectively, provide additional information in the assessment of a patient at risk for CAD. In the case of LDL B, two "normocholesterolemic" groups with CAD are detected, those with normotriglyceridemic HyperapoB and those with hypertriglyceridemic HyperapoB . In all of these syndromes associated with premature CAD, HyperapoB , FCH, and FH, the common denominator is an increased number of LDL particles. A low level of apoA-I may indicate that one of the subfractions of HDL (HDL2) is decreased. HDL2 is generally decreased in disorders where LDL B is elevated, a combination that may be particularly atherogenic. Conversely, elevated apoA-I and HDL cholesterol levels, or decreased LDL cholesterol and LDL B protein levels, are associated with a low prevalence of CAD and longevity. Thus, LDL and HDL levels may be metabolically linked, a relation which is more evident if apoproteins are measured and which may be obscured if apoproteins are not determined. The assessment of dyslipoproteinemia in a patient at risk for CAD might optimally include measurement of LDL B and apoA-I levels, in addition to LDL cholesterol and HDL cholesterol levels.